All that follows is from today’s email on the new COVID-19 Treatment Guidelines sent by the National Institutes Of Health:
New Version of the COVID-19 Treatment Guidelines Published
The COVID-19 Treatment Guidelines Panel (the Panel) is pleased to announce the publication of an updated version of the Coronavirus Disease 2019 (COVID-19) Treatment Guidelines.
In the United States, the prevalence of SARS-CoV-2 Omicron subvariants that are not susceptible to tixagevimab plus cilgavimab (Evusheld) is now more than 90%. Because of this, tixagevimab plus cilgavimab is not authorized for use as COVID-19 pre-exposure prophylaxis (PrEP) in the United States. The Panel now recommends against the use of tixagevimab plus cilgavimab as COVID-19 PrEP. Several sections of the Guidelines have been revised to reflect this recommendation, including Testing for SARS-CoV-2 Infection, Prevention of SARS-CoV-2 Infection, and many of the sections in Special Populations.
Other key updates include:
- The Panel updated the information on breakthrough infection in Clinical Spectrum of SARS-CoV-2 Infection. The Panel also expanded the description of viral or symptom rebound after COVID-19 and prolonged viral shedding with or without symptoms in patients who are immunocompromised and who have COVID-19.
- Information from 2 case series that describe clinical experience with ritonavir-boosted nirmatrelvir in pregnant patients with COVID-19 has been added to Ritonavir-Boosted Nirmatrelvir (Paxlovid).
- The Ivermectin section now includes data from 3 large randomized controlled trials that were published after the last Guidelines update. These trials reported that the use of ivermectin did not provide a clinical benefit for patients with mild to moderate COVID-19. Based on the results from these 3 trials and other studies previously reviewed by the Panel, the Panel recommends against the use of ivermectin for the treatment of COVID-19.
For a full list of updates, please see What’s New in the Guidelines on the COVID-19 Treatment Guidelines website.